Myelodysplastic syndromes : pathobiology and clinical management
Author(s)
Bibliographic Information
Myelodysplastic syndromes : pathobiology and clinical management
(Basic and clinical oncology, 36)
Informa Healthcare, c2009
2nd ed. / edited by David P. Steensma
Available at 1 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Includes bibliographical references and index
HTTP:URL=http://www.loc.gov/catdir/toc/fy0904/2008035268.html Information=Table of contents only
Description and Table of Contents
Description
Written by a team of leading authorities in pathogenesis, diagnostic techniques, and clinical management strategies in myelodysplastic syndrome (MDS), this text provides a concise, easy-to-follow review of the advances in the science, classification, diagnosis, and management of the condition.
An ideal source for hematologists, oncologists, and cancer researchers, this Second Edition features:
a new eight-page color insert
200 color and black-and-white illustrations
reworked content organized into three sections: MDS epidemiology and biology; diagnosis, classification, and prognosis; and MDS therapy
thoroughly updated chapters reflecting a shift from the topical focus as dictated by the evolution of the field
New topics in Myelodysplastic Syndrome include:
del(5q) and 5q-syndrome, CMML, and MDS-MPD overlap syndrome
the reborn DNA methyltransferase inhibiting nucleoside analogs
the diagnosis of chronic myelomonocytic leukemia and other MDS cases with myeloproliferative features
the role of mitochondria and the potential importance of iron overload in MDS
global genomics approaches, such as cDNA expression arrays, array-based comparative genomic hybridization, and single nucleotide polymorphism array
the role of abnormal mitochondrial ferritin accumulation and other mitochondrial metabolic anomalies in MD
other disease-associated alterations, such as abnormalities of B lymphocyte populations in MD
three recently approved drugs: azacitidine, lenalidomide, and decitabine
Table of Contents
1. Myelodysplastic Syndrome: Historical Aspects and Classification. 2. Epidemiology of MDS. 3. Cytogenetics & Molecular Biology of MDS. 4. Global Genomic Approaches to MDS. 5. The Role of Apoptosis in MDS. 6. The Role of Mitochondria in MDS. 7. Defects in Iron Metabolism and Iron Overload in MDS. 8. Therapy-Related MDS and Myeloid Leukemia. 9. Diagnosis of MDS: Criteria and Challenges. 10. Hypocellular MDS and Hypocellulcar Acute Myeloid Leukemias: Relationship to Aplastic Anemia. 11. Diagnostic Utility of Flow Cytometry. 12. Deletion 5q and 5q-Syndrome in MDS. 13. CMML and MDS-MPD Overlap Syndromes. 14. MDS in Children. 15. Prognostic Factors in the Assessment of Patients with MDS. 16. Therapeutic Strategies: The Approsch to Care of Patients w/ MDS, and Criteria for Response. 17. Management of Cytopenias in MDS. 18. Immune Dysregulation And The Role For Immunotherapy in Myelodysplastic Syndrome (MDS). 19. Lenalidomide Therapy in MDS. 20. DNA Methyltransferase Inhibitor Therapy in MDS. 21. Intensive Chemotherapy and Stem Cell Transplantation in MDS.
by "Nielsen BookData"